JHL Biotech appoints new leaders to management team

Four new people step into financial, manufacturing, R&D and engineering roles

JHL Biotech, an emerging biosimilars company in Taiwan and China, says Max Chan has joined the firm as Chief Financial Officer.

The firm has also recently appointed Charles Winter as Vice President of Manufacturing and Technology, and Andreas Nechansky as Vice President of Research and Analytical Operations.

Nick Kotlarski was recently promoted to Vice President of Corporate Engineering.

Chan joins the firm as Chief Financial Officer. He will also oversee business development, public relations, and investor relations. He was previously with TaiGen Biopharmaceuticals, where during his five-year tenure as Chief Financial Officer he facilitated the company's initial public offering in Taiwan.

Winter joined JHL Biotech in July, having previously worked in biologics development at Gilead Sciences. Nechansky joined in September from Vela Labs, which he co-founded and served as Chief Operating Officer and Head of Analytical Operations.

Kotlarski joined JHL in 2013 from Synertec Asia, a life sciences consultancy in Southeast Asia.

You may also like

Design & Build

JHL Biotech opens biosimilars manufacturing facility in China

GE Healthcare delivers world’s first modular manufacturing solution based on single-use bioprocessing technology
Design & Build

JHL Biotech announces mechanical completion of its Wuhan biopharmaceutical manufacturing facility

Speed of construction was made possible by commissioning GE Healthcare Life Sciences' modular factory KUBio
Design & Build

JHL Biotech raises funds to develop biosimilars and build manufacturing capacity

The company intends to continue development of its biosimilar programmes through clinical trials, enable the construction of its facility in Wuhan's commercial manufacturing plant and expand its preclinical novel therapeutic portfolio
Manufacturing

JHL Biotech and Selexis form biologic drug development alliance

Will provide seamless services from cell line development to cGMP manufacturing
Manufacturing

JHL Biotech installs GE’s FlexFactory at Taiwan plant

Will be used for cell line development, process development, and cGMP manufacturing in pre-clinical and early-stage clinical work
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Subscribe now